Vaccine keeps advanced kidney cancer from recurring

Three Years After Experimental Vaccine, These Patients Are Still Cancer-Free
An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune response in all nine patients at high risk for recurrences of their cancer.
New Vaccine Shows Promise For Kidney Cancer
A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.
Experimental vaccine seems to battle advanced kidney cancers
A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report.
BioNTech’s oncology vaccine trial sees all patients living kidney cancer-free
Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping cancer.
Personalized vaccines halt kidney cancer after encouraging phase 1 trial
Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses and keeping patients cancer-free for years.
Kidney Cancer Vaccine Shows Promise in Early Trial
In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.
Personalized cancer vaccine shows potential in kidney cancer
In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.
Cancer vaccine prevents recurrence of advanced kidney cancer in small trial
After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to an experimental, personalized cancer vaccine, researchers reported Feb. 5.
Immunogenic Cancer Vaccine Targets Key Mutations in Kidney Cancer
Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell carcinoma (RCC) and can target key driver mutations and induce antitumor immunity, according to a study published online Feb.
Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows
Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer among adults. In an early-stage clinical trial led by the Dana-Farber Cancer Institute in Boston,
Health Rounds: Vaccine keeps advanced kidney cancer from recurring
Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...
News Medical on MSN23h
Neoantigen vaccine sparks powerful immune defense against kidney cancer
A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...